UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38129 Mersana Therapeutics, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or or ...

Accelerating ADC Innovation …because patients are waiting February 2022 Legal Disclaimer This presentation contains "forward-looking" statements within the meaning of federal securities laws. These forward-looking statements are not statements of historical facts and are based on management's beliefs and assumptions and on information currently available to management. Forward-looking statements include information concerning Mersana Therapeutics, Inc.'s (the "Company's") business strategy and the design, p ...

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q4 2021 Earnings Conference Call February 28, 2022 8:00 AM ET Company Participants James Salierno - Associate Director, Investor Relations. Anna Protopapas - President & CEO Arvin Yang - Senior Vice President & Chief Medical Officer Brian DeSchuytner - Senior Vice President &Chief Financial Officer Conference Call Participants Jonathan Chang - SVB Leerink Boris Peaker - Cowen Colleen Kusy - Baird Capital Kaveri Pohlman - BTIG Jessica Fye - JPMorgan Operator Good mor ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38129 Mersana Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 04-3562403 (State ...

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q3 2021 Earnings Conference Call November 9, 2021 8:00 AM ET Company Participants Sarah Carmody - Executive Director, IR & Corporate Communications Anna Protopapas - President, CEO & Director Arvin Yang - SVP & Chief Medical Officer Timothy Lowinger - Chief Science & Technology Officer Brian DeSchuytner - SVP & CFO Conference Call Participants Boris Peaker - Cowen and Company Kaveri Pohlman - BTIG Daniel Wolle - JPMorgan Chase & Co. Colleen Kusy - Robert W. Baird & C ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-38129 Mersana Therapeutics, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 04-356240 ...

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q2 2021 Earnings Conference Call August 6, 2021 8:00 AM ET Company Participants Sarah Carmody - Executive Director, IR & Corporate Communications Anna Protopapas - President, CEO & Director Brian DeSchuytner - SVP, Finance & Product Strategy Timothy Lowinger - Chief Science & Technology Officer Arvin Yang - SVP & Chief Medical Officer Conference Call Participants Jonathan Chang - SVB Leerink Kaveri Pohlman - BTIG Boris Peaker - Cowen and Company Jessica Fye - JPMorga ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Address of principal executive offices) (Zip Code) (617) 498-0020 (Registrant's telephone number, including area code) Commission file number 001-38129 Mersana Therapeutics, Inc. (Exact name of regist ...

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q1 2021 Earnings Conference Call May 10, 2021 4:30 PM ET Company Participants Sarah Carmody - Executive Director, Investor Relations and Corporate Communications Anna Protopapas - President and CEO Arvin Yang - Chief Medical Officer Tim Lowinger - Chief Science and Technology Officer Brian DeSchuytner - Senior Vice President, Finance and Product Strategy Alejandra Carvajal - Chief Legal Officer Conference Call Participants Jonathan Chang - SVB Leerink Daniel McElligo ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-38129 Mersana Therapeutics, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 04-3562403 (I ...